A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Yubo International Biotech Ltd
YBGJ
$2M
Mkt Cap
$0.01
+0.00%
Yubo International Biotech Ltd (YBGJ) has a 5-year average return on invested capital (ROIC) of -43.6%. This is below average and may indicate limited pricing power.
Yubo International Biotech Ltd (YBGJ) has a market capitalization of $2M. It is classified as a small-cap stock.
Yubo International Biotech Ltd (YBGJ) does not currently pay a regular dividend.
Yubo International Biotech Ltd (YBGJ) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Yubo International Biotech Ltd (YBGJ) generated $-843 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Yubo International Biotech Ltd (YBGJ) reported earnings per share (EPS) of $-0.01 in its most recent fiscal year.
Yubo International Biotech Ltd (YBGJ) has a return on equity (ROE) of 40.1%. This indicates the company generates strong returns for shareholders.
In this Annual Report, unless otherwise specified, the terms “we,” “our,” “us,” the “Company,” or the “Registrant” refer to Yubo International Biotech Limited, a U.S. holding company and New York corporation, formerly known as Magna-Lab, Inc., and its wholly owned subsidiaries, including without limitation, Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands, Platinum International Biotech (Hong Kong) Limited, a company organized under the laws of Hong Kong, and Yubo International Biotech (Chengdu) Limited, a company organized under the laws of the People’s Republic of China (“Yubo Chengdu” or the “WFOE”). The term “Yubo Beijing” refers to Yubo International Biotech (Beijing) Limited, a variable interest entity organized under the laws of the People’s Republic of China, and, through contractual arrangements with, the Chinese operating company. Corporate Overview We are a U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 605K | - | 1.2M |
| Net Income | -1.1M | -1.1M | -1.8M | -1.2M | -1.2M | -1.5M |
| EPS | $-0.01 | $-0.01 | $-0.02 | $-0.10 | - | - |
| Free Cash Flow | -843K | -843K | -1.3M | -739K | -601K | -1.6M |
| ROIC | -110.8% | 0.0% | -91.1% | -56.6% | -460.2% | -26.6% |
| Gross Margin | - | - | - | 69.3% | - | 65.9% |
| Debt/Equity | 0.00 | -0.04 | -0.14 | -0.21 | -1.40 | -35.96 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -1.2M | -1.2M | -1.8M | -1.2M | -1.2M | -1.5M |
| Operating Margin | 0.0% | - | - | -197.6% | - | -124.0% |
| ROE | 0.0% | 40.1% | 67.4% | 99.2% | 346.0% | -297.6% |
| Shares Outstanding | 108M | 108M | 89M | 12M | - | - |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.2M | N/A | 605K | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 65.9% | N/A | 69.3% | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 55K | 58K | 63K | 149K | 58K | 48K | 29K | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -55K | -58K | -63K | -149K | -58K | -48K | -712K | -1.5M | -1.2M | -1.2M | -1.8M | -1.2M | -1.2M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -124.0% | N/A | -197.6% | N/A | N/A | 0.0% |
| Net Income | -106K | -116K | -130K | -224K | -144K | -148K | -712K | -1.5M | -1.2M | -1.2M | -1.8M | -1.1M | -1.1M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -124.0% | N/A | -197.6% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 110K | 0 | 0 | 0 | 0 | 0 | 0 | 212K | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | N/A | N/A | N/A | N/A | N/A | N/A | -61.0% | -26.6% | N/M | -56.6% | -91.1% | 0.0% | -110.8% |
| ROE | 11.1% | 10.8% | 10.9% | 17.0% | 10.0% | N/A | -85.9% | -297.6% | 346.0% | 99.2% | 67.4% | 40.1% | 0.0% |
| ROA | N/A | N/A | N/A | N/A | N/A | -3700.0% | -58.1% | -43.9% | -34.7% | -59.5% | -110.9% | -90.6% | -127.4% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -46K | -63K | -56K | -55K | -55K | -32K | 101K | -1.0M | -601K | -739K | -1.3M | -843K | -843K |
| Free Cash Flow | -46K | -63K | -56K | -55K | -55K | -32K | 59K | -1.6M | -601K | -739K | -1.3M | -843K | -843K |
| Owner Earnings | -46K | -63K | -56K | -55K | -55K | -32K | 88K | -1.7M | -1.3M | -1.5M | -2.4M | -1.8M | -1.8M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 43K | 565K | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 13K | 13K | 18K | 178K | 170K | 168K | 168K |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 29K | 551K | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 13K | 13K | 18K | 178K | 170K | 168K | 168K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 682K | 675K | 618K | 857K | 767K | 767K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -1.1M | N/A | 772K | 386K | 472K | 71K | 71K |
| Cash & Equiv. | 8K | 12K | 11K | 1K | 2K | 1K | 1.4M | 28K | 18K | 6K | 7K | 8K | 8K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 79K |
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | N/A | 0.27 | -35.96 | -1.40 | -0.21 | -0.14 | -0.04 | 0.00 |
| Interest Coverage | -1.1 | -1.0 | -0.9 | -2.0 | -0.7 | -0.5 | -6.8 | -3613.3 | -5263.0 | -3169.0 | -35398.4 | N/A | N/A |
| Equity | -1.0M | -1.1M | -1.3M | -1.4M | -1.5M | N/A | 1.2M | -131K | -565K | -1.8M | -3.4M | -2.0M | -2.0M |
| Total Assets | N/A | N/A | N/A | N/A | N/A | 4K | 2.4M | 4.6M | 2.3M | 1.7M | 1.5M | 847K | 847K |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | 1.3M | 4.7M | 2.9M | 3.5M | 4.8M | 2.8M | 2.8M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | 55K | 39K | 68K | 54K | 51K | 42K | 42K |
| Retained Earnings | -28M | -28M | -28M | -29M | -29M | -29M | -943K | -2.5M | -3.7M | -4.9M | -6.7M | -7.7M | -7.7M |
| Working Capital | -1.0M | -1.1M | -1.3M | -1.4M | -1.5M | -1.7M | 632K | -1.7M | -1.8M | -2.7M | -4.0M | -2.1M | -2.1M |
| Current Assets | 11K | 15K | 14K | 4K | 5K | 4K | 1.9M | 1.1M | 750K | 725K | 683K | 668K | 668K |
| Current Liabilities | 1.0M | 1.1M | 1.3M | 1.4M | 1.5M | 1.7M | 1.3M | 2.8M | 2.5M | 3.4M | 4.7M | 2.8M | 2.8M |
| Per Share Data | |||||||||||||
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | N/A | N/A | -0.10 | -0.02 | -0.01 | -0.01 |
| Owner EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | N/A | N/A | -0.13 | -0.03 | -0.02 | -0.02 |
| Book Value | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | N/A | 0.00 | N/A | N/A | -0.15 | -0.04 | -0.02 | -0.02 |
| Cash Flow/Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | N/A | N/A | -0.06 | -0.02 | -0.01 | -0.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 117.8M | 116.0M | 118.2M | 117.9M | 120.0M | 113.8M | 647.1M | N/A | N/A | 12.0M | 88.8M | 107.9M | 107.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 39.1 | N/A | 52.9 | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.9% | -5.3% | -2.1% | -32.7% | N/A | -55.8% |
| Market Cap | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 54M | 11M | 36M | 4.1M | 0 | 1.5M |
| Avg. Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.41 | 0.17 | 0.27 | 0.40 | 0.00 | 0.01 |
| Year-End Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.45 | 0.09 | 0.30 | 0.05 | 0.00 | 0.01 |
Yubo International Biotech Ltd passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 67.6%.
Yubo International Biotech Ltd (YBGJ) has a 5-year average gross margin of 67.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for Yubo International Biotech Ltd (YBGJ), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Yubo International Biotech Ltd (YBGJ) has a book value per share of $-0.02, based on its most recent annual SEC filing.